Jennifer Mills
Internal Medicine · Bellevue, WANPI 1821103615
Payments from drug & device makers
Across 187 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$419
- Amgen$392
- Johnson & Johnson$376
- Pfizer$348
- Novo Nordisk$330
- AbbVie$312
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,854100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 18 | $419 |
| Amgen | 20 | $392 |
| Johnson & Johnson(2 entities) | 17 | $376 |
| Pfizer | 16 | $348 |
| Novo Nordisk | 18 | $330 |
| AbbVie(2 entities) | 13 | $312 |
| AstraZeneca | 11 | $214 |
| Lilly USA, LLC | 10 | $199 |
| Kowa Pharmaceuticals America, Inc. | 6 | $124 |
| Merck | 6 | $112 |
| Alfasigma USA, Inc. | 5 | $107 |
| Astellas Pharma US Inc | 6 | $93 |
| Teva Pharmaceuticals USA, Inc. | 4 | $87 |
| Novartis | 4 | $66 |
| Sanofi-aventis U.S. LLC | 2 | $56 |
| Lundbeck LLC | 2 | $56 |
| Impulse Dynamics (USA) Inc. | 2 | $55 |
| Dexcom, Inc. | 2 | $54 |
| Abbott | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Medtronic | 1 | $31 |
| Radius Health, Inc. | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Avion Pharmaceuticals | 2 | $30 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Echosens North America, Inc. | 1 | $22 |
| GSK | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
How this compares
$3,854 in reported general payments places this provider in the 90th percentile of 2,038 internal medicine providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 59 | $72,475 |
| OzempicSemaglutide | 42 | $56,697 |
| JardianceEmpagliflozin | 29 | $30,675 |
| XareltoRivaroxaban | 26 | $26,319 |
| MounjaroTirzepatide | 21 | $24,510 |
| MyrbetriqMirabegron | 26 | $19,189 |
| ProliaDenosumab | 11 | $18,979 |
| DexilantDexlansoprazole | 15 | $7,081 |
| TrintellixVortioxetine Hydrobromide | 12 | $6,127 |
| SynthroidLevothyroxine Sodium | 42 | $3,876 |
| Estradiol | 20 | $1,882 |
| Mirtazapine | 37 | $1,532 |
| RivastigmineRivastigmine Tartrate | 12 | $1,456 |
| Omeprazole | 50 | $1,363 |
| Atorvastatin Calcium | 128 | $1,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $348 | $72,47559 claims |
| Novo NordiskOzempic | $330 | $56,69742 claims |
| Boehringer IngelheimJardiance | $419 | $30,67529 claims |
| Johnson & JohnsonXarelto | $376 | $26,31926 claims |
| Lilly USA, LLCMounjaro | $199 | $24,51021 claims |
| Astellas Pharma US IncMyrbetriq | $93 | $19,18926 claims |
| AmgenProlia | $392 | $18,97911 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant, Trintellix | $37 | $13,20827 claims |
| AbbVieSynthroid | $312 | $3,87642 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $50763 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Bellevue
- Lawrence LoebBellevue$784K
- Gary SchusterBellevue$16K
- Allen GeltzerBellevue$14K
- Tatyana KutsyBellevue$13K
- Sabrina BenjaminOlympia$7.9M
- Ryan AhernSeattle$7.3M
- Eric KleinOlympia$2.4M
- Scott RamseySeattle$2M
- Vidya MenonTacoma$1.8M
- Peter ShalitSeattle$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.